Howland Capital Management LLC Makes New $261,000 Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Howland Capital Management LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,466 shares of the medical equipment provider’s stock, valued at approximately $261,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Equity Investment Corp bought a new stake in shares of Zimmer Biomet during the third quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC grew its position in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after buying an additional 577,320 shares during the period. Van ECK Associates Corp increased its stake in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after acquiring an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $41,588,000. Finally, FMR LLC boosted its stake in Zimmer Biomet by 27.6% during the third quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after acquiring an additional 162,384 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.6 %

Shares of ZBH stock opened at $101.01 on Monday. The company has a market capitalization of $20.11 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The company’s fifty day moving average price is $107.34 and its 200-day moving average price is $108.08. Zimmer Biomet Holdings, Inc. has a one year low of $99.93 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.95%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 21.57%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZBH. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Barclays decreased their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday. Oppenheimer reduced their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Finally, Wells Fargo & Company increased their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.